Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Pityriasis Rosea Treatment & Management

  • Author: Robert A Schwartz, MD, MPH; Chief Editor: Dirk M Elston, MD  more...
 
Updated: Jun 02, 2016
 

Approach Considerations

Pityriasis rosea (PR) is a self-limited disease; treatment is supportive. Water, sweat, and soap may cause irritation and should be avoided early in the disease. Topical zinc oxide and calamine lotion are useful for pruritus. If the disease is severe or widespread (eg, vesicular PR), topical or oral steroids may be used. Ultraviolet (UV) radiation therapy has been demonstrated to be effective for PR but may leave postinflammatory pigmentation at the site of the PR lesion.[47]

For patients in whom superficial tinea infection is a concern or possibility, topical antifungal therapy can be used. Some data suggest that the antiviral agent acyclovir could hasten resolution.[48, 49]

No restriction of activity or isolation is necessary. No evidence suggests that children with PR should be prevented from attending school.

Next

Pharmacologic Therapy and Phototherapy

In most cases, it is not necessary to treat PR.[50] The rash usually disappears in a few weeks, with no sequelae. Although various treatments have been attempted, the efficacy of most of them has not been definitively proved.[51]

Generally, patient education (eg, to avoid exposure to irritant agents [eg, harsh soaps, fragrances, hot water, wool, and synthetic fabrics], tight clothing, and scratching), coupled with reassurance that the rash will resolve, is all that is needed. However, it can be helpful to institute measures aimed at relieving bothersome symptoms (eg, pruritus).

Pruritus is commonly associated with PR and often responds to bland emollients, oral antihistamines, or topical preparations containing calamine, menthol-phenol, pramoxine, colloidal starch, or oatmeal. If the rash is severe, topical steroids can be applied. It must be kept in mind that although steroids alleviate the pruritus, they do not modify the eruption. The sedative effect of the antihistamines may help the patient to sleep better at night.

Systemic steroids are not recommended because they may exacerbate the disease. However, some dermatologists use prednisone (0.5-1 mg/kg/day for 7 days) in selected patients with severe pruritus, vesicular lesions, or the potential for significant postinflammatory hyperpigmentation, to suppress both pruritus and the exanthem.

UV-B phototherapy, starting at 80% of the minimum erythrogenic dose, may rapidly relieve pruritus in resistant cases.[47] If itching is not controlled, the dose should be increased by 20% until symptoms decrease. However, one study failed to find improvement in pruritus with UV-B light therapy but did note decreased lesion severity. The possibility of postinflammatory pigmentation with light therapy must be kept in mind.[52, 53] An alternative approach is to administer low-dose UV-A1 phototherapy 2-3 times a week until resolution.[54]

In an atypical case of vesicular PR, considerable improvement was noted with the administration of 20 mg of dapsone twice daily.[39]

Some evidence suggests that acyclovir may be useful. Treatment in the first week of symptom onset with 1 g of acyclovir taken orally 5 times a day for 7 days in adults has been shown to shorten the duration of disease and may be of benefit.[55, 56] Lower dosages of 400 mg 5 times a day for 1 week may be equally effective.[48] However, acyclovir has been shown to be ineffective against HHV-6 and HHV-7.[55]

A number of antibiotics have been tried, without much success. In a small clinical trial, 1 g of erythromycin taken orally 4 times daily in adults or 25-40 mg/kg divided 4 times daily in children for 2 weeks led to early resolution of symptoms.[57] However, another study did not find erythromycin to be useful in this condition.[58] Azithromycin also was not found to be effective for children with PR.[59]

In a randomized trial involving 42 patients with a clinical diagnosis of PR who were treated with either high-dose oral acyclovir or standard-dose oral erythromycin, all of the patients in the 2 groups exhibited a complete response after 8 weeks.[60] Although the study findings indicated that both agents were helpful, patients receiving acyclovir showed a better response, which was statistically significant in weeks 1, 2, 4, and 6.

Management of PR in patients with evidence of group A streptococcal infection may be warranted. The possible risk of scarlet fever and poststreptococcal sequelae should be considered.[61]

Previous
Next

Consultations

Consultation with a dermatologist is warranted for patients with severe pruritus or disease that necessitates systemic steroid therapy, patients who desire UV-B therapy, or patients with atypical presentations of PR.

Consultation with an infectious disease specialist should be considered for individuals with immunosuppression, such as recipients of solid organ transplants or hematopoietic stem cell transplants.

Pregnant women with PR should be referred to a high-risk maternal-fetal medicine specialist.

Previous
Next

Long-Term Monitoring

Generally, PR resolves within 12 weeks, and no follow-up is necessary in most cases. However, follow-up care may be provided to ensure that the rash is improving. Patients with moderate-to-severe pruritus who are receiving topical steroids should be followed up by phone or in a return visit in 1-2 weeks.

Most cases of PR do not recur,[62] but some patients may develop the condition more than once, in which event alternative diagnoses or immune suppression should be considered. If the diagnosis is in doubt or if the disease persists past the expected duration period, further evaluation is advised. PR that has persisted for longer than 3 months is often better classified as pityriasis lichenoides chronica.

Previous
 
 
Contributor Information and Disclosures
Author

Robert A Schwartz, MD, MPH Professor and Head of Dermatology, Professor of Pathology, Pediatrics, Medicine, and Preventive Medicine and Community Health, Rutgers New Jersey Medical School; Visiting Professor, Rutgers University School of Public Affairs and Administration

Robert A Schwartz, MD, MPH is a member of the following medical societies: Alpha Omega Alpha, New York Academy of Medicine, American Academy of Dermatology, American College of Physicians, Sigma Xi

Disclosure: Nothing to disclose.

Coauthor(s)

Richard Lichenstein, MD Professor, Pediatric Emergency Department, University of Maryland School of Medicine

Richard Lichenstein, MD is a member of the following medical societies: American Medical Association, American Academy of Pediatrics

Disclosure: Nothing to disclose.

Camila K Janniger, MD Clinical Professor of Dermatology, Clinical Associate Professor of Pediatrics, Chief of Pediatric Dermatology, Rutgers New Jersey Medical School

Camila K Janniger, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

Chief Editor

Dirk M Elston, MD Professor and Chairman, Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina College of Medicine

Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

Acknowledgements

Robert A Allen, MD Staff Physician, Department of Dermatology, Drexel University College of Medicine-Hahnemann Hospital

Robert A Allen, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, and American Medical Association

Disclosure: Nothing to disclose.

Jerry Balentine, DO Professor of Emergency Medicine, New York College of Osteopathic Medicine; Executive Vice President, Chief Medical Officer, Attending Physician in Department of Emergency Medicine, St Barnabas Hospital

Jerry Balentine, DO is a member of the following medical societies: American College of Emergency Physicians, American College of Osteopathic Emergency Physicians, American College of Physician Executives, American Osteopathic Association, and New York Academy of Medicine

Disclosure: Nothing to disclose.

Kevin P Connelly, DO Clinical Assistant Professor, Department of Pediatrics, Division of General Pediatrics and Emergency Care, Virginia Commonwealth University School of Medicine; Medical Director, Paws for Health Pet Visitation Program of the Richmond SPCA; Pediatric Emergency Physician, Emergency Consultants Inc, Chippenham Medical Center

Kevin P Connelly, DO is a member of the following medical societies: American Academy of Pediatrics, American College of Osteopathic Pediatricians, and American Osteopathic Association

Disclosure: Nothing to disclose.

Burke A Cunha, MD Professor of Medicine, State University of New York School of Medicine at Stony Brook; Chief, Infectious Disease Division, Winthrop-University Hospital

Burke A Cunha, MD is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, and Infectious Diseases Society of America

Disclosure: Nothing to disclose.

Pamela L Dyne, MD Professor of Clinical Medicine/Emergency Medicine, University of California, Los Angeles, David Geffen School of Medicine; Attending Physician, Department of Emergency Medicine, Olive View-UCLA Medical Center

Pamela L Dyne, MD is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Mark W Fourre, MD Program Director, Department of Emergency Medicine, Maine Medical Center; Associate Clinical Professor, Department of Surgery, University of Vermont School of Medicine

Disclosure: Nothing to disclose.

Rajendra Kapila, MD, MBBS Professor of Medicine, Department of Medicine, University of Medicine and Dentistry of New Jersey-New Jersey Medical School

Rajendra Kapila, MD, MBBS is a member of the following medical societies: American College of Physicians, American Medical Association, Infectious Diseases Society of America, and Infectious Diseases Society of New Jersey

Disclosure: Nothing to disclose.

Thomas M Kerkering, MD Chief of Infectious Diseases, Virginia Tech Carilion School of Medicine

Thomas M Kerkering, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, American Public Health Association, American Society for Microbiology, American Society of Tropical Medicine and Hygiene, Infectious Diseases Society of America, Medical Society of Virginia, and Wilderness Medical Society

Disclosure: Nothing to disclose.

Mark G Lebwohl, MD Chairman, Department of Dermatology, Mount Sinai School of Medicine

Mark G Lebwohl, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Amgen/Pfizer Honoraria Consulting; GlaxoSmithKline None Investigator; Novartis Honoraria Consulting; Ranbaxy None Consulting; Pfizer None Consulting; BioLineRX, Ltd. Honoraria Consulting; Celgene Corporation Consulting; Clinuvel None Investigator; Eli Lilly & Co. Honoraria Consulting; Genentech None Consulting

Daniel R Lucey, MD, MPH Chief, Fellowship Program Director, Department of Internal Medicine, Division of Infectious Diseases, Washington Hospital Center; Professor, Department of Internal Medicine, Uniformed Services University of the Health Sciences

Daniel R Lucey, MD, MPH is a member of the following medical societies: Alpha Omega Alpha and American College of Physicians

Disclosure: Nothing to disclose.

Amal Mattu, MD, FACEP, FAAEM Professor and Vice Chair, Department of Emergency Medicine, University of Maryland School of Medicine

Amal Mattu, MD, FACEP, FAAEM is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Jeffrey Meffert, MD Assistant Clinical Professor of Dermatology, University of Texas School of Medicine at San Antonio

Jeffrey Meffert, MD is a member of the following medical societies: American Academy of Dermatology, American Medical Association, Association of Military Dermatologists, and Texas Dermatological Society

Disclosure: Nothing to disclose.

Giuseppe Micali, MD Head, Professor, Department of Dermatology, University of Catania School of Medicine, Italy

Giuseppe Micali, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

Maria R Nasca, MD, PhD Assistant Professor, Department of Dermatology, University of Catania School of Medicine, Italy

Disclosure: Nothing to disclose.

Robert L Rogers, MD Staff Physician, Departments of Internal Medicine and Surgery, Division of Emergency Medicine, University of Maryland

Robert L Rogers, MD is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, and American College of Physicians-American Society of Internal Medicine

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Richard P Vinson, MD Assistant Clinical Professor, Department of Dermatology, Texas Tech University Health Sciences Center, Paul L Foster School of Medicine; Consulting Staff, Mountain View Dermatology, PA

Richard P Vinson, MD is a member of the following medical societies: American Academy of Dermatology, Association of Military Dermatologists, Texas Dermatological Society, and Texas Medical Association

Disclosure: Nothing to disclose.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

References
  1. Allen RA, Janniger CK, Schwartz RA. Pityriasis rosea. Cutis. 1995 Oct. 56(4):198-202. [Medline].

  2. González LM, Allen R, Janniger CK, Schwartz RA. Pityriasis rosea: an important papulosquamous disorder. Int J Dermatol. 2005 Sep. 44(9):757-64. [Medline].

  3. Browning JC. An update on pityriasis rosea and other similar childhood exanthems. Curr Opin Pediatr. 2009 Aug. 21(4):481-5. [Medline].

  4. Finnish Medical Society Duodecim. Syphilis. EBM Guidelines. Jun 6 2008.

  5. Emre S, Akoglu G, Metin A, Demirseren DD, Isikoglu S, Oztekin A, et al. The Oxidant and Antioxidant Status in Pityriasis Rosea. Indian J Dermatol. 2016 Jan-Feb. 61 (1):118. [Medline].

  6. Neoh CY, Tan AW, Mohamed K, Sun YJ, Tan SH. Characterization of the inflammatory cell infiltrate in herald patches and fully developed eruptions of pityriasis rosea. Clin Exp Dermatol. 2010 Apr. 35(3):300-4. [Medline].

  7. Drago F, Broccolo F, Zaccaria E, Malnati M, Cocuzza C, Lusso P, et al. Pregnancy outcome in patients with pityriasis rosea. J Am Acad Dermatol. 2008 May. 58(5 Suppl 1):S78-83. [Medline].

  8. Drago F, Ciccarese G, Rebora A, Broccolo F, Parodi A. Pityriasis Rosea: A Comprehensive Classification. Dermatology. 2016 Apr 21. [Medline].

  9. Chuh AA, Chan PK, Lee A. The detection of human herpesvirus-8 DNA in plasma and peripheral blood mononuclear cells in adult patients with pityriasis rosea by polymerase chain reaction. J Eur Acad Dermatol Venereol. 2006 Jul. 20(6):667-71. [Medline].

  10. Blauvelt A. Skin diseases associated with human herpesvirus 6, 7, and 8 infection. J Investig Dermatol Symp Proc. 2001 Dec. 6(3):197-202. [Medline].

  11. Broccolo F, Drago F, Careddu AM, Foglieni C, Turbino L, Cocuzza CE, et al. Additional evidence that pityriasis rosea is associated with reactivation of human herpesvirus-6 and -7. J Invest Dermatol. 2005 Jun. 124(6):1234-40. [Medline].

  12. Canpolat Kirac B, Adisen E, Bozdayi G, Yucel A, Fidan I, Aksakal N, et al. The role of human herpesvirus 6, human herpesvirus 7, Epstein-Barr virus and cytomegalovirus in the aetiology of pityriasis rosea. J Eur Acad Dermatol Venereol. 2009 Jan. 23(1):16-21. [Medline].

  13. Drago F, Malaguti F, Ranieri E, Losi E, Rebora A. Human herpes virus-like particles in pityriasis rosea lesions: an electron microscopy study. J Cutan Pathol. 2002 Jul. 29(6):359-61. [Medline].

  14. Kempf W, Adams V, Kleinhans M, Burg G, Panizzon RG, Campadelli-Fiume G, et al. Pityriasis rosea is not associated with human herpesvirus 7. Arch Dermatol. 1999 Sep. 135(9):1070-2. [Medline].

  15. Watanabe T, Kawamura T, Jacob SE, Aquilino EA, Orenstein JM, Black JB, et al. Pityriasis rosea is associated with systemic active infection with both human herpesvirus-7 and human herpesvirus-6. J Invest Dermatol. 2002 Oct. 119(4):793-7. [Medline].

  16. Chuh A, Chan H, Zawar V. Pityriasis rosea--evidence for and against an infectious aetiology. Epidemiol Infect. 2004 Jun. 132(3):381-90. [Medline]. [Full Text].

  17. Rebora AE, Drago F. A novel influenza a (H1N1) virus as a possible cause of pityriasis rosea? A comment. J Eur Acad Dermatol Venereol. 2011 Aug. 25(8):991-2; author reply 991. [Medline].

  18. Rebora A, Drago F, Broccolo F. Pityriasis rosea and herpesviruses: facts and controversies. Clin Dermatol. 2010 Sep-Oct. 28(5):497-501. [Medline].

  19. Mubki TF, Bin Dayel SA, Kadry R. A case of Pityriasis rosea concurrent with the novel influenza A (H1N1) infection. Pediatr Dermatol. 2011 May-Jun. 28(3):341-2. [Medline].

  20. Prantsidis A, Rigopoulos D, Papatheodorou G, Menounos P, Gregoriou S, Alexiou-Mousatou I, et al. Detection of human herpesvirus 8 in the skin of patients with pityriasis rosea. Acta Derm Venereol. 2009 Nov. 89(6):604-6. [Medline].

  21. Drago F, Broccolo F, Rebora A. Pityriasis rosea: an update with a critical appraisal of its possible herpesviral etiology. J Am Acad Dermatol. 2009 Aug. 61(2):303-18. [Medline].

  22. Drago F, Ranieri E, Malaguti F, Battifoglio ML, Losi E, Rebora A. Human herpesvirus 7 in patients with pityriasis rosea. Electron microscopy investigations and polymerase chain reaction in mononuclear cells, plasma and skin. Dermatology. 1997. 195(4):374-8. [Medline].

  23. Kwon NH, Kim JE, Cho BK, Park HJ. A novel influenza a (H1N1) virus as a possible cause of pityriasis rosea?. J Eur Acad Dermatol Venereol. 2011 Mar. 25(3):368-9. [Medline].

  24. Drago F, Ciccarese G, Rebora A, Parodi A. Pityriasis rosea following human papillomavirus vaccination. Braz J Infect Dis. 2015 Mar-Apr. 19(2):224-5. [Medline].

  25. Drago F, Ciccarese G, Javor S, Parodi A. Vaccine-induced pityriasis rosea and pityriasis rosea-like eruptions: a review of the literature. J Eur Acad Dermatol Venereol. 2014 Dec 29. [Medline].

  26. Rajpara SN, Ormerod AD, Gallaway L. Adalimumab-induced pityriasis rosea. J Eur Acad Dermatol Venereol. 2007 Oct. 21(9):1294-6. [Medline].

  27. Guarneri C, Polimeni G, Nunnari G. Pityriasis rosea during etanercept therapy. Eur Rev Med Pharmacol Sci. 2009 Sep-Oct. 13(5):383-7. [Medline].

  28. Sezer E, Erkek E, Cetin E, Sahin S. Pityriasis rosea-like drug eruption related to rituximab treatment. J Dermatol. 2013 Feb 27. [Medline].

  29. Bangash HK, Finch T, Petronic-Rosic V, Sethi A, Abramsohn E, Lindau ST. Pityriasis Rosea-Like Drug Eruption Due to Nortriptyline in a Patient With Vulvodynia. J Low Genit Tract Dis. 2013 Jan 22. [Medline].

  30. Lai YW, Chou CY, Shen WW, Lu ML. Pityriasis rosea-like eruption associated with clozapine: a case report. Gen Hosp Psychiatry. 2012 Nov-Dec. 34(6):703.e5-7. [Medline].

  31. Chuang TY, Ilstrup DM, Perry HO, Kurland LT. Pityriasis rosea in Rochester, Minnesota, 1969 to 1978. J Am Acad Dermatol. 1982 Jul. 7(1):80-9. [Medline].

  32. Drago F, Broccolo F, Javor S, Drago F, Rebora A, Parodi A. Evidence of human herpesvirus-6 and -7 reactivation in miscarrying women with pityriasis rosea. J Am Acad Dermatol. 2014 Jul. 71(1):198-9. [Medline].

  33. Drago F, Broccolo F, Ciccarese G, Rebora A, Parodi A. Persistent pityriasis rosea: an unusual form of pityriasis rosea with persistent active HHV-6 and HHV-7 infection. Dermatology. 2015. 230(1):23-6. [Medline].

  34. Robati RM, Toossi P. Plantar herald patch in pityriasis rosea. Clin Exp Dermatol. 2009 Mar. 34(2):269-70. [Medline].

  35. Vidimos AT, Camisa C. Tongue and cheek: oral lesions in pityriasis rosea. Cutis. 1992 Oct. 50(4):276-80. [Medline].

  36. Zawar V. Pityriasis amiantacea-like eruptions in scalp: a novel manifestation of pityriasis rosea in a child. Int J Trichology. 2010 Jul. 2(2):113-5. [Medline]. [Full Text].

  37. Osawa A, Haruna K, Okumura K, Taneda K, Mizuno Y, Suga Y. Pityriasis rosea showing unilateral localization. J Dermatol. 2011 Jun. 38(6):607-9. [Medline].

  38. Zawar V, Godse K. Annular groin eruptions: pityriasis rosea of vidal. Int J Dermatol. 2011 Feb. 50(2):195-7. [Medline].

  39. Anderson CR. Dapsone treatment in a case of vesicular pityriasis rosea. Lancet. 1971 Aug 28. 2(7722):493. [Medline].

  40. Sezer E, Saracoglu ZN, Urer SM, Bildirici K, Sabuncu I. Purpuric pityriasis rosea. Int J Dermatol. 2003 Feb. 42(2):138-40. [Medline].

  41. Singh V, Sharma M, Narang T, Madan M. Vesicular palmoplantar pityriasis rosea. Skinmed. 2012 Mar-Apr. 10(2):116-8. [Medline].

  42. Bhalla N, Tambe S, Zawar V, Joshi R, Jerajani H. Localized purpuric lesions in a case of classical pityriasis rosea. Indian J Dermatol Venereol Leprol. 2014 Nov-Dec. 80(6):551-3. [Medline].

  43. Ang CC, Tay YK. Blaschkoid pityriasis rosea. J Am Acad Dermatol. 2009 Nov. 61(5):906-8. [Medline].

  44. Zawar V, Godse K. Segmental lesions in pityriasis rosea: a rare presentation. Skinmed. 2011 Nov-Dec. 9(6):382-4. [Medline].

  45. Amer A, Fischer H, Li X. The natural history of pityriasis rosea in black American children: how correct is the "classic" description?. Arch Pediatr Adolesc Med. 2007 May. 161(5):503-6. [Medline].

  46. Verardino GC, Azulay-Abulafia L, Macedo PM, Jeunon T. Pityriasis amiantacea: clinical-dermatoscopic features and microscopy of hair tufts. An Bras Dermatol. 2012 Jan-Feb. 87(1):142-5. [Medline].

  47. Stulberg DL, Wolfrey J. Pityriasis rosea. Am Fam Physician. 2004 Jan 1. 69(1):87-91. [Medline].

  48. Rassai S, Feily A, Sina N, Abtahian S. Low dose of acyclovir may be an effective treatment against pityriasis rosea: a random investigator-blind clinical trial on 64 patients. J Eur Acad Dermatol Venereol. 2011 Jan. 25(1):24-6. [Medline].

  49. Ganguly S. A Randomized, Double-blind, Placebo-Controlled Study of Efficacy of Oral Acyclovir in the Treatment of Pityriasis Rosea. J Clin Diagn Res. 2014 May. 8(5):YC01-4. [Medline]. [Full Text].

  50. Drago F, Rebora A. Treatments for pityriasis rosea. Skin Therapy Lett. 2009 Mar. 14(3):6-7. [Medline].

  51. Chuh AA, Dofitas BL, Comisel GG, Reveiz L, Sharma V, Garner SE, et al. Interventions for pityriasis rosea. Cochrane Database Syst Rev. 2007 Apr 18. CD005068. [Medline].

  52. Arndt KA, Paul BS, Stern RS, Parrish JA. Treatment of pityriasis rosea with UV radiation. Arch Dermatol. 1983 May. 119(5):381-2. [Medline].

  53. Leenutaphong V, Jiamton S. UVB phototherapy for pityriasis rosea: a bilateral comparison study. J Am Acad Dermatol. 1995 Dec. 33(6):996-9. [Medline].

  54. Lim SH, Kim SM, Oh BH, Ko JH, Lee YW, Choe YB, et al. Low-dose Ultraviolet A1 Phototherapy for Treating Pityriasis Rosea. Ann Dermatol. 2009 Aug. 21(3):230-6. [Medline]. [Full Text].

  55. Drago F, Vecchio F, Rebora A. Use of high-dose acyclovir in pityriasis rosea. J Am Acad Dermatol. 2006 Jan. 54(1):82-5. [Medline].

  56. Ehsani A, Esmaily N, Noormohammadpour P, Toosi S, Hosseinpour A, Hosseini M, et al. The comparison between the efficacy of high dose acyclovir and erythromycin on the period and signs of pitiriasis rosea. Indian J Dermatol. 2010 Jul-Sep. 55(3):246-8. [Medline]. [Full Text].

  57. Sharma PK, Yadav TP, Gautam RK, Taneja N, Satyanarayana L. Erythromycin in pityriasis rosea: A double-blind, placebo-controlled clinical trial. J Am Acad Dermatol. 2000 Feb. 42(2 Pt 1):241-4. [Medline].

  58. Rasi A, Tajziehchi L, Savabi-Nasab S. Oral erythromycin is ineffective in the treatment of pityriasis rosea. J Drugs Dermatol. 2008 Jan. 7(1):35-8. [Medline].

  59. Amer A, Fischer H. Azithromycin does not cure pityriasis rosea. Pediatrics. 2006 May. 117(5):1702-5. [Medline].

  60. Amatya A, Rajouria EA, Karn DK. Comparative study of effectiveness of oral acyclovir with oral erythromycin in the treatment of Pityriasis rosea. Kathmandu Univ Med J (KUMJ). 2012 Jan-Mar. 10(37):57-61. [Medline].

  61. Krishnamurthy K, Walker A, Gropper CA, Hoffman C. To treat or not to treat? Management of guttate psoriasis and pityriasis rosea in patients with evidence of group A Streptococcal infection. J Drugs Dermatol. 2010 Mar. 9(3):241-50. [Medline].

  62. Zawar V, Kumar R. Multiple recurrences of pityriasis rosea of Vidal: a novel presentation. Clin Exp Dermatol. 2009 Jul. 34(5):e114-6. [Medline].

  63. Drago F, Ciccarese G, Rebora A, Parodi A. The efficacy of macrolides and acyclovir in pityriasis rosea. Indian J Dermatol Venereol Leprol. 2015 Jan-Feb. 81(1):56. [Medline].

 
Previous
Next
 
Herald patch. Image courtesy of Drexel Department of Dermatology slide collection.
Christmas tree distribution of lesions on trunk. Image courtesy of Drexel Department of Dermatology slide collection.
Histopathologic features of pityriasis rosea. Image courtesy of Gary R Kantor, MD, Department of Dermatology, Drexel University, Philadelphia, PA.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.